INTRODUCTION
Inflammation is the immunological defense mechanism by which the body fights infection or injury from bacteria, viruses and other pathogens. The defining clinical features of inflammation are known in Latin as rubor (redness), calor (warmth), tumor (swelling) and dolor (pain). These hallmarks of inflammation were first described by Aurelius Cornelius, a Roman physician and medical writer who lived from about 30 B.C. to 45 A.D. The redness and swelling that occurs at the site of a wound is due to the widening blood vessels to allow specialized white blood cells to enter and battle the pathogens. Following this process, the inflammation fades and healing begins. Excessive or inadequate activation of the system can have serious effects, as can the failure of the inactivation mechanism. In the early 1970s, aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) were found to inhibit cyclooxygenase (COX), which produces prostaglandins (PGs), a class of physiological and pathophysiological inflammatory mediators. 1 Since then, the biosynthetic cascade of arachidonic acid (AA) has been the subject of intense research. This is because AA, having been previously liberated from phospholipids using various stimuli, can be metabolized by the COX pathway into PGs and thromboxane A2, or by the lipoxygenase (LOX) pathways to hydroperoxyeicosateraenoic acids (HpETEs), hydroxyeicosateraenoic acids (HETEs) and leukotrienes (LTs) (Fig. 1 ). These two proteins play a vital role in inflammation by controlling the intensity and duration of pain, as well as the occurrence of fever, swelling and heat of an affected area. Although steroidal anti-inflammatory drugs and NSAIDs are currently used to treat acute inflammation, these drugs have not been successful in curing chronic inflammatory diseases, such as bronchiectasis, rheumatoid arthritis (RA), osteoarthritis (OA), and inflammatory bowel disease (ulcerative colitis and Crohn's disease). Recently, Vioxx and Celebrex, two blockbuster drugs used to treat arthritis, were withdrawn from the drug market due to their cardiovascular side effects. These cases provide examples of the unknown side effects produced by synthetic drugs, and suggest that an evaluation of the long-term effects of drugs may be required.
Alternatively, a large number of dietary polyphenols have been consumed in food, and their anti-inflammatory activities have been reported. Polyphenols can be classified into four different groups: flavonoids, stillbenes, lignas, and phenolic acids (Fig. 2) . These compounds have received considerable attention from the public. In fact, 12 out of the 40 anti-inflammatory drugs approved between 1983 and 1994 were derived from or based on these natural products. 2 These molecules are secondary metabolites of plants and are generally involved in the defense mechanism against ultraviolet radiation and insects. Some of the polyphenols found to be beneficial to health were characterized as naturally-occurring toxicants in plants. In excess, some polyphenols resulted in growth depression in poultry, livestock and laboratory animals. However, the intake of small amounts of polyphenols in food has a potent effect on reducing chronic diseases in animal models. Epidemiological studies have indicated that populations who consume foods rich in specific polyphenols have a lower incidence of chronic inflammatory diseases. Kuhnau et al. calculated that dietary polyphenol intake in the US was~1 g/day. 3 Some studies have subsequently provided more precise individual data regarding the intake of various classes of dietary polyphenols. Flavonols (one of the flavonoids) have been more extensively studied, and the consumption of these substances has been estimated at 20-25 mg/day in the US. 4 The plasma concentrations of flavonoids are usually <10 μM and the steady-state levels are typically <1 μM. 5 However, the concentrations of total polyphenols may be higher than those of flavonoids.
We have been studying the effects of several dietary polyphenol compounds (including resveratrol, genistein, catechin, and indole-3-carbinol) on chronic diseases in humans, such as inflammation and cancer. [6] [7] [8] [9] The potential molecular mechanisms of their anti-inflammatory activities have also been suggested to include, but not limited to, the inhibition of enzymes related to inflammation, such as cyclooxygenase and lipoxygenase, and many others including PPAR, NOS, NF-κB, and NAG-1. Thus, polyphenols can influence many pathways, and other compounds may also affect the same pathways. The detailed mechanisms by which each polyphenol induces anti-inflammation remain to be elucidated. In this review, we summarized the current findings of the molecular targets of polyphenols as anti-inflammatory compounds. We focused on two molecular aspects: the arachidonic acid (AA)-dependent pathway and the AA-independent pathway. Cyclooxygenase, lipoxygenase, and PLA2 are discussed as AA-dependent pathway proteins by polyphenols, whereas NOS, NF-κB, PPAR, and NAG-1 are discussed as AA-independent pathway proteins. There is great potential for dietary polyphenols to become the next generation of dietary factors to confer health effects for inflammation beyond synthetic drugs. Further, dietary polyphenols may provide an excellent model system for the development of more effective drugs in the future.
ARACHIDONIC ACID DEPENDENT PATHWAY COX inhibition
An anti-inflammatory effect is believed to result from inhibiting the formation of prostaglandins by prostaglandin H synthase (COX, also called cyclooxygenase), which converts arachidonic acid (AA) released by membrane phospholipids into prostaglandins. Two isoforms of prostaglandin H synthase, COX-1 and COX-2, have been identified, and one variant form (COX-3) has recently been reported as well. 10 COX-1 is constitutively expressed in many tissues, while the expression of COX-2 is regulated by mitogens, tumor promoters, and growth factors. 11 NSAIDs are widely used in the treatment of inflammatory diseases. Since aspirin was synthesized, a number of aspirin-like drugs have also been developed. Aspirin and other NSAIDs (also known as conventional NSAIDs that block COX-1 and COX-2) induce gastric ulcerization and kidney failure due to COX-1 inhibition. COX-1 is necessary for the protection of the stomach lining, so interfering with its activity can cause gastrointestinal disturbances ranging from simple discomfort to bleeding ulcers. This hypothesis was confirmed when newly developed drugs that specifically inhibited COX-2 were shown to have a lower rate of gastrointestinal bleeding when compared to conventional NSAIDs. 12 However, the "good" COX-1
versus "bad" COX-2 dichotomy has proven overly simplistic. COX-2 has been shown to exert normal physiological effects, including the regulation of vascular and renal blood flows. 13 The identifica-tion of COX-2 was not expected to increase the effectiveness of NSAID therapy, since conventional NSAIDs inhibited both COX-1 and COX-2. However, the identification of cyclooxygenase 3 (COX-3) may contribute to the elucidation of the inflammatory process. 10 COX-3 has also raised many questions by researchers studying the effects of acetaminophen. The weak level of COX-3 inhibition induced by acetaminophen probably does not occur with standard oral dosages of acetaminophen (0.5-1 g/day). Thus, other hypotheses regarding acetaminophen's mechanisms of action should be considered. Although the marketing of new COX-2 inhibitors has emphasized the advantages of not blocking the necessary COX-1 pathway, infrequent reports of gastrointestinal problems still exist from the use of these medications. Both Celebrex and Vioxx were withdrawn from the market in 2005 due to an increase in cardiovascular risks, likely caused by the thromboxane formed via the COX-1 pathway. 14 Therefore, a clinical trial that involves patients switching from one synthetic agent to a different agent could be valuable. Several compounds that are consumed daily in various foods may provide alternative tools for treating inflammatory diseases by acting as COX inhibitors. In 1980, Baumann et al. were the first to report, in a study that assessed rat medullar COX activity, that some dietary polyphenols, such as galangin and luteolin, inhibit AA peroxidation. 15 Since then, several researchers have reported that many dietary polyphenols inhibit COX activity at the transcriptional level as well as at the enzyme level. For instance, Landolfi et al. found that flavone, chrysin, apigenein, and phloretin depressed COX activity and inhibited platelet aggregation. 16 The flavonoids, 6-hydroxykaempferol, and quercetagenin isolated from T. parthenium (feverfew), and 6-hydroxyluteolin and scutellarein isolated from T. vulgaris (tansy) were shown to inhibit COX activity in leukocytes. 17 The triterpenes sasanquol isolated from C. sasanqua (Theaceae) and 3β-p-hydroxybenzoyldehydrotumulosic acid from the fungus P. cocos (Polyporaceae) produced activity against 12-O-tetradecanoylphobol-13-acetate (TPA) and also AA-induced ear inflammation in mice, 18 which was probably caused by the COX-2 inhibition. Pre-treatment with green tea extract enriched with catechin and epigallocatechin gallate (EGCG) by gavage inhibited COX-2 expression that was induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) in mouse skin. Similarly, EGCG down-regulated COX-2 in TPA-stimulated human mammary epithelial cells (MCF-10A) in culture. 19 Both the green tea catechin and the EGCG displayed COX inhibition activity in LPS-induced macrophages 20 and inhibited IL-1β-dependent pro-inflammatory signal transduction in cultured respiratory epithelial cells. 21 The stillbene compound resveratol possesses anti-inflammatory activity because it suppresses carragenen-induced pedal edema via the inhibition of COX activity. 22 Furthermore, resveratrol inhibits TPA-induced COX-2 expression at the transcriptional level. 23 Thus, the mechanism by which resveratrol exerts anti-inflammatory activity may be related to the inhibition of either COX transcription or COX activity. Studies using isolated bovine COX-1 and COX-2 enzymes showed that curcumin had significantly higher inhibitory effects on the peroxidase activity of COX-1 than that of COX-2. 24 EGCG and resveratrol were the most effective COX-1 inhibitors among those tested in the study. 20 Genistein down-regulates COX-2 promoter activity in colon cancer cells transfected with a COX-2 reporter gene system. 25 Wogonin and sophoraflavanone-G down-regulate COX-2 expression from TNF-α treated NIH/3T3 cells and LPS treated RAW cells, respectively. This suggests that the COX-2 downregulation of skin fibroblasts may in part be one of the anti-inflammatory mechanisms these compounds exert against skin inflammation such as atopic dermatitis. 26, 27 Although many studies have reported that polyphenols inhibit COX-1 or COX-2, it has not yet been reported that polyphenols inhibit COX-3. Collectively, several polyphenols were reported to have anti-inflammatory effects, as assessed by COX inhibition. COX inhibition by polyphenols may account for these anti-inflammatory effects, which reduce prostaglandin synthesis. Therefore, it should be noted that the concurrent use of polyphenols and NSAIDs could be beneficial or deleterious, and thus necessitates constant attention by healthcare providers.
LOX inhibition
LOXs are the enzymes responsible for generating hydroxyl acids and leukotrienes (LTs) from AA (Fig. 1) . There are three distinct LOX isozymes in that affect different cells and tissues. 15-LOX synthesizes anti-inflammatory 15-HETE, 5; 12-LOX is involved in provoking inflammatory/allergic disorders; and 5-LOX produces 5-HETE and LTs, which are potent chemoattractants and lead to the development of asthma. 12-LOX synthesizes 12-HETE, which aggregates platelets and induces the inflammatory response. Therefore, the effect of polyphenols on 5-and 12-LOXs has been extensively studied in order to elucidate the anti-inflammatory properties. Flavonols, including kaempferol, quercetin, morin and myricetin, were found to be 5-LOX inhibitors. 28 With IC50 values ranging from 1.0 to 18.7 M, hamamelitannin and μ the galloylated proanthocyanidins were found to be the most potent inhibitors of 5-LOX. 29 Some prenylated flavonoids, such as artonin E, are the most effective inhibitors of porcine leukocyte 5-LOX. 30 An anti-inflammatory neolignan sibyllenone from Ocotea bullata (black stinkwood) was also active against 5-LOX. 31 Baicalein was reported to selectively inhibit platelet 5-LOX. 32 Curcumin blocks the activity of human recombinant 5-LOX. 24 In contrast, there are few reports regarding 12-LOX inhibition. Using bovine PMNs and 12-LOX from bovine platelets, kuwanson C and quercetin potently inhibit 12-LOX activity, 33 with IC50 values of 19 and 12 M, respectively. In comparison, the μ IC50 value of the known LOX inhibitor nordihydroguaiaretic acid (NDGA) is 2.6 M. μ
COX and LOX inhibitions
The LOX pathway produces leukotrienes. When only COX-2 is blocked, the LOX pathway still produces the potent mediators of inflammation. The condition may even be exacerbated by blocking only the inflammatory cascade of COX-2, which allows the LOX branch to accelerate the formation of leukotrienes. Dual inhibition of LOX/COX has been suggested to be a desirable approach in the development of new drugs for anti-inflammation. 34 Thus far, researchers have not been able to bypass certain limiting barriers to produce such a medication. This is important since some researchers have found that COX-2 inhibition alone will exacerbate the production of pro-inflammatory cytokines such as TNF-α and IL-1β, both of which cause destructive damage to inflammatory sites. Hong et al. demonstrated that curcumin fits in this category of agents. 24 Many other polyphenols are also the inhibitors of both COX and LOX. Subsequently, a general structure rule has been found: more COX inhibitions and less LOX inhibitions with polyphenols contain few hydroxyl substituents.
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PLA2 inhibition
Phospholipase A2 (PLA2), the enzyme that cleaves phospholipids producing lysophospholipids and free fatty acids, was originally identified as an intracellular protein involved in cell signaling and in the production of free fatty acids, such as arachidonic acid. 36 It is known that PLA2
plays an important role in the inflammation process. The inhibition of PLA2 could be a potential therapeutic agent for curing human inflammatory diseases (Fig. 1) . Phospholipases are mainly classified into three large groups: secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2), and calcium-independent PLA2 (iPLA2). It is now known that this family is comprised of at least 10 members with distinct cellular distributions and growing therapeutic potential. 37 Specifically, sPLA 2 -V and sPLA2-X are selectively expressed in the epithelium of the human airway. sPLA2-IIA is low but becomes highly expressed during inflammation and sepsis as a result of LPS, cytokine and NF-κB induction. This enzyme is now associated with allergic rhinitis, rheumatoid arthritis, and septic shock. Finally, the selective expression of sPLA2-V and sPLA2-X suggests that these enzymes should be evaluated as targets for airway dysfunction. Thus, the PLA2 family represents a therapeutic target with ever-increasing potential. It is likely that PLA 2 is an important intra-and extracellular mediator of inflammation. The modulation of sPLA2 and/or cPLA2 activity is important in controlling the inflammatory process. Quercetin was found to be an effective inhibitor of PLA2 in human 38 and rabbit 39 leukocytes. It was also demonstrated that quercetin selectively inhi-bited sPLA 2 -II, compared to its lower inhibition of sPLA2-IB. 40 Quercetagetin, kaempferol- 
AA-INDEPENDENT PATHWAY Peroxisome proliferator activated receptors (PPARs)
Many inflammatory cytokines are produced and regulated at the transcriptional level, which can either enhance or inhibit the inflammation process. One such molecular link between proinflammatory cytokines and transcription factor is peroxisome proliferator-activated receptors (PPARs). PPARs are nuclear hormone receptors that are activated by specific endogenous and exogenous ligands. 44 Three isoforms (α, / β δ, and γ) have been identified and are encoded by separate genes. Among those, PPAR activation is responsible for α the pleiotropic effects of peroxisome proliferators, such as enzyme induction, peroxisome proliferation, liver enlargement and anti-inflammation. 45 PPAR also plays a critical role in the α regulation of cellular uptake and β-oxidation of fatty acids. 46 In contrast, PPARδ (also known as PPARβ) is widely expressed with relatively higher levels in the brain, colon, and skin. Although there have been extensive studies on PPAR and α inflammation, very little is known about the effect of PPARδ on inflammation. In contrast, PPARγ has been further divided into three subtypes: PPARγ1, γ2, and γ3. 47, 48 All PPAR isotypes form a heterodimeric complex with the retinoid X receptor (RXR), and the complex binds to the PPAR response element (PPRE), which functions as the central regulator of cellular differentiation, 49 apoptosis, 50,51 inflammatory responses, 52, 53 lipid metabolism and metabolic disease. 54 The first study that provided evidence of a potential role for PPARs in the inflammatory response showed that the duration of the inflammatory response is prolonged in PPARα-KO mice in response to LTB4. 55 Since then, a growing body of evidence has suggested that PPAR ligands inhibit pro-inflammatory cytokines in monocytes. 52 Thus, the activation of PPAR results in anti-inflammatory activity. Genistein increased the expression of genes involved in lipid catabolism; this effect is not estrogen receptor-dependent, but instead is PPAR -dependent. α 56 EGCG also binds to PPARα.
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Amentoflavone up-regulates PPARγ expression in A549 human lung epithelial cells. 58 Few studies have regarded polyphenols as PPAR ligands, but it is probable that polyphenols may also affect PPAR protein expression, which results in the activation of the PPAR pathway. It is notable that the PPAR pathways are tightly connected to other inflammatory pathways including NF-κB, COX-2 expression, and pro-inflammatory cytokines. These results demonstrate that the activation of PPARs by certain polyphenols represent another possibility the treatment of chronic inflammatory diseases.
Nitric oxide synthase (NOS)
Nitric oxide (NO), a gaseous free radical, is released by a family of enzymes, including endothelia NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS), with the formation of stoichiometric amounts of L-citrulline from L-arginine. 59 Excessive and prolonged iNOS-mediated NO generation has attracted attention because of its relevance to inflammation. Since NO is one of the inflammatory mediators, the inhibition of NO by the extracts of edible plants has been reported. 60 Using LPS/cytokine-treated macrophages or macrophage-like cell lines, quercetin was found to inhibit the production of NO. 61 However, mechanism studies have shown that compounds downregulate iNOS expression, which subsequently results in reducing the amount of NO production.
Several flavonoid derivatives, including apigenin, quercetin, and morin, have also inhibited NO production from LPS/interferonγ-activated C6 astrocytes. 62 Quercetin markedly inhibits the production of TNF-α and NO by LPS-activated macrophages, and TNF-inhibition may occur post-α transcriptionally, whereas iNOS inhibition usually occurs at the transcriptional level. 63 Many polyphenols, including 6-gingerol, 64 EGCG, 65 resveratrol, 66 indole-3-carbinol, 67 and oroxylin A, 68 inhibit NOS expression in LPS-induced RAW264.7 cells. These effects are probably mediated by NF-κB inhibition.
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NF-B κ
Nuclear transcription factor κB (NF-κB), which was discovered by David Baltimore in 1986, is a ubiquitous factor that resides in the cytoplasm. When it becomes activated, it is translocated to the nucleus, where it induces gene transcription. NF-κB is activated by free radicals, inflammatory stimuli, carcinogens, tumor promoters, endotoxins, γ-radiation, ultraviolet (UV) light, and X-rays. Upon activation, NF-κB induces the expression of more than 200 genes that have been shown to suppress apoptosis and induce cellular transformation, proliferation, invasion, metastasis, chemoresistance, radio-resistance, and inflammation. The activated form of NF-κB has been found to mediate cancer, atherosclerosis, myocardial infarction, diabetes, allergy, asthma, arthritis, and other inflammatory diseases. It is not surprising that NF-κ B has been linked to this wide variety of diseases, because most diseases are caused by poorly regulated inflammation. Therefore, agents that can suppress NF-κB activation, in principle, have the potential to prevent, delay the onset of, or treat inflammatory diseases.
Several sesquiterpene lactones demonstrated anti-inflammatory properties by inhibiting the binding of the transcription factor NF-κB, as assessed by a gel shift assay. 70 Quercetin was reported to suppress TNF-induced expression of α IL-8 and monocyte chemoattractant protein (MCP-1) due to its ability to inhibit the activation of NF-κB. 71 Quercetin also inhibited the NF-κB pathway without any modification of c-Jun N-terminal kinase activity both in vivo and in vitro. 72 Caffeic acid phenethyl ester (CAFE), a natural product secreted by the honeybee, inhibited cerebral inflammatory responses by reducing the activity of NF-κB. 73 Resveratrol has also been known to inhibit NF-κB activity, although resveratrol may possess anti-inflammatory properties via an NF-κ B-independent mechanism. 74 Recently, it has been reported that indole-3-carbinol, found in Brassica sp. vegetables (such as cabbage, cauliflower, and brussel spouts), inhibits NF-κB and NF-κB-regulated gene expression. 75 The inhibition of NF-κB by several polyphenols may explain the antiinflammatory effects of these compounds.
NAG-1
NAG-1 (NSAID activated gene-1) was identified by PCR-based subtractive hybridization from an NSAID-induced library in cyclooxygenase-negative cells as a divergent member of the TGF-β superfamily. 76 The induction of NAG-1 by NSAIDs is an important COX-independent mechanism by which some of these proven anti-inflammatory compounds mediate their effects. 77 NAG-1 has been identified by other groups, as macrophage inhibitory cytokine-1 (MIC-1), 78 placental transformation growth factor-(PTGFB), β 79 prostate derived factor (PDF), 80 growth differentiation factor 15 (GDF-15), 81 and placental bone morphogenetic protein (PLAB). 82 The diversity of biological functions represented by this nomenclature suggests that the NAG-1 protein has broad activity in inflammation, cancer, and differentiation. The molecular mechanisms responsible for these functions have yet to be determined in detail. Experimental evidence suggests that NAG-1 may share at least some of the common functions of TGF-β superfamily cytokines. For instance, TGF-β1 induces apoptosis and cell growth arrest in epithelial cells, and mice treated with TGF-β1 died of widespread inflammation. Indeed, NAG-1 expression reduces TNF-α secretion in macrophages, 78 and inhibits the proliferation of primitive hemopoietic progenitors 83 and several epithelial cancer cell lines, 76, 77, 79, 84, 85 reflecting the activity of a multifunctional cytokine. In contrast to other members of the TGF-superfamily, NAG-1 is induced not β only by several NSAIDs, but also by several dietary compounds. As described in Table 1, NAG-1 was initiated by many of the polyphenols described in this review. All of the listed compounds induced NAG-1 expression, except EC and EGC, which indicates the structure-specific expression of NAG-1 induction. Overall, NAG-1 could prove to be a good molecular target protein for examining the anti-inflammatory and/or anti-cancer activity of other compounds.
CONCLUSION
Dietary polyphenols comprise a vast array of biologically active compounds that are ubiquitous in plants, many of which have been used in traditional Oriental medicine for thousands of years. In this review, we summarized the different targets of dietary polyphenols by their anti-inflammatory effects. Given that certain polyphenols are known to affect more than one protein, it is necessary consider possibility that any single compound may affect multiple mechanisms. However, most of the previous clinical studies have used foods or beverages containing a mixture of different polyphenols, and the exact mechanisms of the most active polyphenol components remain largely unknown. Therefore, these factors should be taken into consideration along with bioavailability in order to improve the experimental design and interpret the observed effects. In addition, since absorption, metabolism, and elimination vary widely among polyphenols, these factors should also be considered Furthermore, such characterization of these compounds could validate the importance of dietary polyphenol compounds in human health and encourage their use as templates for further structural development of more effective and safe chemopreventive compounds. 
